These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11600364)

  • 1. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.
    Bentoucha A; Robert J; Dega H; Lounis N; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3109-12. PubMed ID: 11600364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
    Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
    Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice.
    Dega H; Robert J; Bonnafous P; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2367-72. PubMed ID: 10952581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin.
    Lefrançois S; Robert J; Chauffour A; Ji B; Jarlier V
    Antimicrob Agents Chemother; 2007 Feb; 51(2):645-50. PubMed ID: 17101676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
    Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.
    Converse PJ; Tyagi S; Xing Y; Li SY; Kishi Y; Adamson J; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2015; 9(6):e0003823. PubMed ID: 26042792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin.
    Marsollier L; Prévot G; Honoré N; Legras P; Manceau AL; Payan C; Kouakou H; Carbonnelle B
    Int J Antimicrob Agents; 2003 Dec; 22(6):562-6. PubMed ID: 14659652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.
    Almeida DV; Converse PJ; Li SY; Tyagi S; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2013; 7(2):e2085. PubMed ID: 23469308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.
    Ji B; Chauffour A; Robert J; Jarlier V
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1912-6. PubMed ID: 18391038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
    Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
    Chauffour A; Robert J; Veziris N; Aubry A; Jarlier V
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005066. PubMed ID: 27755552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
    Ji B; Chauffour A; Robert J; Lefrançois S; Jarlier V
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3737-9. PubMed ID: 17664316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice].
    Nakanaga K; Saito H; Ishii N; Goto M
    Kekkaku; 2004 May; 79(5):333-9. PubMed ID: 15211873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice.
    Dhople AM; Namba K
    J Chemother; 2003 Feb; 15(1):47-52. PubMed ID: 12678414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance.
    Choi GE; Shin SJ; Won CJ; Min KN; Oh T; Hahn MY; Lee K; Lee SH; Daley CL; Kim S; Jeong BH; Jeon K; Koh WJ
    Am J Respir Crit Care Med; 2012 Nov; 186(9):917-25. PubMed ID: 22878281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease.
    Converse PJ; Xing Y; Kim KH; Tyagi S; Li SY; Almeida DV; Nuermberger EL; Grosset JH; Kishi Y
    PLoS Negl Trop Dis; 2014; 8(1):e2618. PubMed ID: 24392174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.